OGN - Organon Q1 2022 Earnings Preview

Organon (NYSE:OGN) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $1.30 and the consensus Revenue Estimate is $1.52B (+0.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue estimates have seen 0 upward revisions and 4 downward. The company's stock rose on Feb. 17, the day it reported its Q4 results which beat analysts' estimates. For 2022, Organon, a Merck spinoff focused on women’s health and biosimilars, projects $6.1B - $6.4B revenue vs. estimates of $6.26B. During the quarter, OGN announced an agreement with Daré Bioscience (DARE) for Xaciato, an FDA-approved therapy for bacterial vaginosis. Stock has risen 3.4% YTD.

For further details see:

Organon Q1 2022 Earnings Preview